Clinical Trial Finder

Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.

Filters
Sort by
A Multicentre Trial Evaluating the Efficacy and Safety of Oral Decitabine Tetrahydrouridine (NDec) in Patients With Sickle Cell Disease

This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease.

Locations

398 United States sites

155 India sites

125 United Kingdom sites

75 Canada sites

75 Italy sites

50 France sites

50 Spain sites

50 Turkey sites

49 Greece sites

25 South Africa sites

4 Switzerland sites

Age

> 18 Years

Phase

Phase 2

LEARN MORE
A Randomized Double-Blind Phase IIA Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

This study is designed to evaluate the efficacy, safety and pharmacokinetics of crovalimab compared with placebo as adjunct therapy in the prevention of VOEs in participants with SCD.

Locations

153 Brazil sites

120 Turkey sites

77 Spain sites

72 United States sites

72 Italy sites

48 France sites

19 United Kingdom sites

Age

12 Years - 55 Years

Phase

Phase 2

LEARN MORE
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

This Phase 3 study will assess the safety and efficacy of inclacumab, a P-selectin inhibitor, in reducing the frequency of vaso-occlusive crises (VOCs) in approximately 240 adult and adolescent participants (≥ 12 years of age) with sickle cell disease (SCD).

Locations

799 United States sites

426 Brazil sites

285 Nigeria sites

240 Kenya sites

187 Turkey sites

144 Colombia sites

144 France sites

144 Italy sites

96 Lebanon sites

95 United Kingdom sites

48 Germany sites

47 Saudi Arabia sites

47 Oman sites

47 Tanzania sites

Age

> 12 Years

Phase

Phase 3

LEARN MORE
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

This Phase 3 study will assess the safety and efficacy of a single dose of inclacumab, a P-selectin inhibitor, for a vaso-occlusive crisis (VOC) after an index VOC in participants with sickle cell disease (SCD).

Locations

494 United States sites

266 Nigeria sites

224 Brazil sites

190 Kenya sites

190 Turkey sites

114 Italy sites

76 Colombia sites

76 Lebanon sites

72 France sites

38 Oman sites

38 Germany sites

36 Saudi Arabia sites

Age

> 12 Years

Phase

Phase 3

LEARN MORE
An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.

Locations

134 United States sites

78 Belgium sites

78 Brazil sites

78 Turkey sites

52 France sites

52 Italy sites

52 Lebanon sites

26 Colombia sites

26 Oman sites

26 Germany sites

26 Spain sites

Age

> 6 Months Years

Phase

Phase 4

LEARN MORE
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis

The purpose of the Phase 2 CSEG101B2201 study is to confirm and to establish appropriate dosing and to evaluate the safety in pediatric participants ages 6 months to <18 years with a history of VOC with or without HU/HC, receiving crizanlizumab for 2 years.

Locations

504 United States sites

120 Spain sites

96 Belgium sites

72 Brazil sites

72 Colombia sites

72 Germany sites

72 India sites

72 Italy sites

72 United Kingdom sites

48 Canada sites

48 Lebanon sites

48 Turkey sites

24 Oman sites

24 Switzerland sites

24 France sites

Age

6 Months - 17 Years

Phase

Phase 2

LEARN MORE